Panacea Biotec (BOM:531349) Piotroski F-Score: 5 (As of Jul. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
54 GF Score
Price ₹538.20
GF Value ₹359.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Panacea Biotec Piotroski F-Score?

Panacea Biotec BOM:531349 +0.09% 54 Piotroski F-Score is 5 as of Jul. 15, 2026, which is at its 10-year median of 5.00. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,333 Biotechnology companies, Panacea Biotec ranks better than 84.77% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panacea Biotec has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Panacea Biotec's Piotroski F-Score or its related term are showing as below:

BOM:531349' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Panacea Biotec was 7. The lowest was 3. And the median was 5.

Panacea Biotec  (BOM:531349) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Panacea Biotec Piotroski F-Score Related Terms


Panacea Biotec Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec Piotroski F-Score Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 7.00 4.00 5.00

Panacea Biotec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 0.00 0.00 5.00

BOM:531349 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Panacea Biotec's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Biotec Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacea Biotec's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Panacea Biotec's Piotroski F-Score falls into.


BOM:531349
54GF Score
Panacea Biotec Ltd BOM:531349
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹-54 Mil.
Cash Flow from Operations was ₹167 Mil.
Revenue was ₹6,398 Mil.
Gross Profit was ₹3,593 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (12897.46 + 12621.7) / 2 = ₹12759.58 Mil.
Total Assets at the begining of this year (Mar25) was ₹12,897 Mil.
Long-Term Debt & Capital Lease Obligation was ₹237 Mil.
Total Current Assets was ₹5,130 Mil.
Total Current Liabilities was ₹3,487 Mil.
Net Income was ₹-84 Mil.

Revenue was ₹5,591 Mil.
Gross Profit was ₹3,596 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (12408.21 + 12897.46) / 2 = ₹12652.835 Mil.
Total Assets at the begining of last year (Mar24) was ₹12,408 Mil.
Long-Term Debt & Capital Lease Obligation was ₹150 Mil.
Total Current Assets was ₹5,452 Mil.
Total Current Liabilities was ₹3,670 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panacea Biotec's current Net Income (TTM) was -54. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panacea Biotec's current Cash Flow from Operations (TTM) was 167. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-53.7/12897.46
=-0.00416361

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-83.7/12408.21
=-0.00674553

Panacea Biotec's return on assets of this year was -0.00416361. Panacea Biotec's return on assets of last year was -0.00674553. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Panacea Biotec's current Net Income (TTM) was -54. Panacea Biotec's current Cash Flow from Operations (TTM) was 167. ==> 167 > -54 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=236.6/12759.58
=0.01854293

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=150/12652.835
=0.01185505

Panacea Biotec's gearing of this year was 0.01854293. Panacea Biotec's gearing of last year was 0.01185505. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=5130.4/3486.8
=1.47137777

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=5451.79/3669.93
=1.4855297

Panacea Biotec's current ratio of this year was 1.47137777. Panacea Biotec's current ratio of last year was 1.4855297. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Panacea Biotec's number of shares in issue this year was 61.023. Panacea Biotec's number of shares in issue last year was 61.095. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3592.9/6397.7
=0.56159245

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3595.5/5590.9
=0.64309861

Panacea Biotec's gross margin of this year was 0.56159245. Panacea Biotec's gross margin of last year was 0.64309861. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=6397.7/12897.46
=0.49604341

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5590.9/12408.21
=0.4505807

Panacea Biotec's asset turnover of this year was 0.49604341. Panacea Biotec's asset turnover of last year was 0.4505807. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+0+1+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panacea Biotec has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Panacea Biotec (BOM:531349) has a Piotroski F-Score of 5 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Panacea Biotec and its competitors. This is near median its historical median of 5.00. Over the past decade, Panacea Biotec's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Panacea Biotec ranks #203 out of 1333 companies in the Biotechnology industry, placing it in the top 15.2%.
Is Panacea Biotec's Piotroski F-Score too high?
Panacea Biotec's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Panacea Biotec's value of 5 is 66.7% above this industry median. Based on the distribution chart, Panacea Biotec ranks #203 out of 1333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #203 out of 1333 companies for Piotroski F-Score. This places Panacea Biotec in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Panacea Biotec's value of 5 is 66.7% above this benchmark. Historically, Panacea Biotec's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Panacea Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Biotec's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 66.7% above the Biotechnology industry median of 3.00. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Piotroski F-Score is 5 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued. The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92. GuruFocus considers Panacea Biotec to be Significantly Overvalued.

Key valuation signals for BOM:531349:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
  • GF Score™: 54/100 with 3 warning signs
  • Industry Position: 66.7% above the Biotechnology median (#203 of 1333)

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score

Get the complete analysis for BOM:531349

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹538.20
Price
₹359.92
GF Value